慢性肾脏病患者尿毒症症状相关代谢物:CRIC研究
本研究为横断面设计,纳入1761例未透析的CRIC队列CKD患者,检测448种血浆代谢物,采用三种统计模型识别与尿毒症症状严重度相关的溶质。共发现17种代谢物水平升高与至少一种症状加重相关,9种呈反向相关,多数与eGFR中度相关,部分还关联肾衰竭或死亡风险。
要点
- 在未透析CKD患者中,多种血浆代谢物与尿毒症症状严重度独立相关。
- 17种代谢物水平升高与症状加重相关,9种与症状减轻相关。
- 多数相关代谢物与eGFR呈中度相关,部分还预测肾衰竭或死亡。
核心结论
- 代谢组学分析识别出多个与CKD成人尿毒症症状相关的溶质,但需外部验证和机制研究。
研究设计与样本
- 横断面研究,纳入1761例未接受透析治疗的慢性肾功能不全队列(CRIC)CKD患者。
- 检测448种已知血浆代谢物,采用多变量线性回归、LASSO回归和随机森林三种模型筛选。
主要发现
- 参与者平均eGFR为43mL/min/1.73m2,44%为女性,41%为非西班牙裔黑人。
- 尿毒症症状(疲劳、厌食、瘙痒、恶心、感觉异常、疼痛)患病率范围为22%至55%。
- 17种代谢物水平升高与至少一种尿毒症症状严重度增加相关,9种代谢物呈反向相关。
- 许多相关代谢物与eGFR至少呈中度相关(Pearson r≥0.5),部分还关联肾衰竭或死亡风险。
关键数值与推荐
- 在至少2种建模方法中选出的代谢物被认定为「总体显著」。
- 症状通过肾脏疾病生活质量-36量表的单个条目评估。
临床怎么用
- 这些代谢物可能为理解CKD尿毒症症状的病理生理提供线索,但尚无 validated 标志物用于临床。
- 当前发现不支持将代谢物检测常规用于症状管理,需进一步验证。
局限性
- 缺乏第二个独立队列进行外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The toxins that contribute to uremic symptoms in patients with chronic kidney disease (CKD) are unknown. We sought to apply complementary statistical modeling approaches to data from untargeted plasma metabolomic profiling to identify solutes associated with uremic symptoms in patients with CKD. STUDY DESIGN: Cross-sectional. SETTING & PARTICIPANTS: 1,761 Chronic Renal Insufficiency Cohort (CRIC) participants with CKD not treated with dialysis. PREDICTORS: Measurement of 448 known plasma metabolites. OUTCOMES: The uremic symptoms of fatigue, anorexia, pruritus, nausea, paresthesia, and pain were assessed by single items on the Kidney Disease Quality of Life-36 instrument. ANALYTICAL APPROACH: Multivariable adjusted linear regression, least absolute shrinkage and selection operator linear regression, and random forest models were used to identify metabolites associated with symptom severity. After adjustment for multiple comparisons, metabolites selected in at least 2 of the 3 modeling approaches were deemed "overall significant." RESULTS: Participant mean estimated glomerular filtration rate was 43mL/min/1.73m2, with 44% self-identifying as female and 41% as non-Hispanic Black. The prevalence of uremic symptoms ranged from 22% to 55%. We identified 17 metabolites for which a higher level was associated with greater severity of at least one uremic symptom and 9 metabolites inversely associated with uremic symptom severity. Many of these metabolites exhibited at least a moderate correlation with estimated glomerular filtration rate (Pearson's r≥0.5), and some were also associated with the risk of developing kidney failure or death in multivariable adjusted Cox regression models. LIMITATIONS: Lack of a second independent cohort for external validation of our findings. CONCLUSIONS: Metabolomic profiling was used to identify multiple solutes associated with uremic symptoms in adults with CKD, but future validation and mechanistic studies are needed. PLAIN-LANGUAGE SUMMARY: Individuals living with chronic kidney disease (CKD) often experience symptoms related to CKD, traditionally called uremic symptoms. It is likely that CKD results in alterations in the levels of numerous circulating substances that, in turn, cause uremic symptoms; however, the identity of these solutes is not known. In this study, we used metabolomic profiling in patients with CKD to gain insights into the pathophysiology of uremic symptoms. We identified 26 metabolites whose levels were significantly associated with at least one of the symptoms of fatigue, anorexia, itchiness, nausea, paresthesia, and pain. The results of this study lay the groundwork for future research into the biological causes of symptoms in patients with CKD.
引用
- Wulczyn KE, Shafi T, Anderson A, et al. Metabolites Associated With Uremic Symptoms in Patients With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2024. PMID: 38266973. doi:10.1053/j.ajkd.2023.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。